---
title: "預覽：Eikon Therapeutics, Inc 將於明日進行首次公開募股"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274836033.md"
description: "Eikon Therapeutics, Inc 將於 2026 年 2 月 5 日在納斯達克上市，股票代碼為 EIKN。預計每股價格在 16.00 美元至 18.00 美元之間，內部鎖定期為 180 天，將於 2026 年 8 月 4 日結束。該公司專注於開發針對嚴重未滿足醫療需求的創新藥物"
datetime: "2026-02-04T15:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274836033.md)
  - [en](https://longbridge.com/en/news/274836033.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274836033.md)
---

# 預覽：Eikon Therapeutics, Inc 將於明日進行首次公開募股

**Eikon Therapeutics, Inc** (NASDAQ:EIKN) IPO will take place February, 05 on the NASDAQ exchange under the ticker EIKN.

The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on August 04, 2026.

**See also:** **Benzinga IPO Calendar**

### About Eikon Therapeutics, Inc

Eikon Therapeutics, Inc is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs.

**See also:** **Benzinga's Most Shorted Stocks**

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### 相關股票

- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [ANIK.US](https://longbridge.com/zh-HK/quote/ANIK.US.md)
- [NBSE.ESC.US](https://longbridge.com/zh-HK/quote/NBSE.ESC.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)

## 相關資訊與研究

- [鉅亨速報 - Factset 最新調查：Cytokinetics IncCYTK-US 的目標價調升至 98 元，幅度約 3.16%](https://longbridge.com/zh-HK/news/285260197.md)
- [朗齊生醫 LXP108 一期臨牀試驗安全性表現穩健 開發進程持續向前](https://longbridge.com/zh-HK/news/285172960.md)
- [鉅亨速報 - Factset 最新調查：Krystal Biotech Inc(KRYS-US) EPS 預估上修至 7.99 元，預估目標價為 311.00 元](https://longbridge.com/zh-HK/news/285129897.md)
- [鉅亨速報 - Factset 最新調查：Kymera Therapeutics Inc(KYMR-US) EPS 預估下修至-3.46 元，預估目標價為 119.00 元](https://longbridge.com/zh-HK/news/285070732.md)
- [阿尼卡醫療公佈 2026 年第一季度財務業績 | ANIK 股票新聞](https://longbridge.com/zh-HK/news/284554290.md)